Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2017 · 10-Q
Revenue$3.86M$3.86M+6.7% vs Q2 2016 Net Income-$6.39M-$6.39MN/M vs Q2 2016 EPS Diluted-$0.65-$0.65N/M vs Q2 2016 Gross Profit$1,976,000+11.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,423,000N/M Margins · derivedGross margin51.3%+2.3 pt vs Q2 2016
Operating margin-93.3%−13.2 pt vs Q2 2016
Net margin-165.8%−87.0 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 10, 2017 · 41 d after period end